Appendix 3B with prospectus
Filed with ASX · · 73 pages · English
Earlier from Mesoblast
- Mesoblast Receives RMAT For LVAD Heart Failure Patients
- Mesoblasts P3 GVHD Trial Completes Enrollment
- Mesoblast Grants TiGenix License For Treatment of Fistulae
- MSB Named Global Technology Leader In Cell Therapy Industry
- Response to ASX Aware Letter Query
Later from Mesoblast
- Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
- GVHD Day 28 Results Presentation
- MSB Enters Into $75 Million Non-Dilutive Credit Facility
- Partnership For Allogeneic Cell-based Cancer Immunotherapies
- Key Day 100 Survival Results In P3 GvHD Trial
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast